8-K: Fennec Pharmaceuticals Reports Strong 2024 Sales Growth and Advances PEDMARK Commercialization

Fennec Pharmaceuticals announces a 40% year-over-year increase in PEDMARK net product sales, reaching $29.6 million for the full year 2024, and provides a business update.

Summary

• Fennec Pharmaceuticals reported its full year and fourth quarter financial results for the period ended December 31, 2024.
• Full-year PEDMARK net product sales reached $29.6 million, a 40% increase year-over-year.
• Q4 2024 PEDMARK net product sales were $7.9 million.
• The company delivered a Q4 2024 EBITDA loss of $0.6 million.
• Fennec has $26.6 million in cash, cash equivalents, and short-term investments as of December 31, 2024.
• The company completed an early repayment of $13 million of its convertible debt facility.
• PEDMARQSI is now commercially available in the United Kingdom and Germany.
• Results from the Japan clinical trial (STS-J01) are expected in the second half of 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, successful commercial launches, and a healthy cash position. However, the EBITDA loss and net loss temper the overall sentiment.

Positives

• Strong growth in PEDMARK net product sales, with a 40% increase for the full year 2024.
• Increased penetration in the AYA market opportunity.
• Healthy cash position of $26.6 million as of December 31, 2024.
• Early repayment of $13 million of convertible debt, reducing future interest expenses and potential dilution.
• Successful commercial launch of PEDMARQSI in the United Kingdom and Germany.
• All medical compendia have incorporated Fennec's clinical updates, and AHFS has updated its content to reflect and differentiate PEDMARK in accordance with its labeling.
• PEDMARK is recommended for the AYA population by the National Comprehensive Cancer Network, or NCCN, with a 2A endorsement.

Negatives

• The company reported a Q4 2024 EBITDA loss of $0.6 million.
• Cash flow from operations decreased by $0.6 million for the fourth quarter of 2024.
• The company recorded a net loss of $(1,619) thousand for the three months ended December 31, 2024.

Risks

• The company's future performance is subject to risks and uncertainties inherent in the business.
• Regulatory and guideline developments may change.
• Scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards.
• Clinical results may not be replicated in actual patient settings.
• The available market for the company's products may not be as large as expected.
• The company may not be able to obtain necessary capital when needed on acceptable terms or at all.

Future Outlook

With the right foundational strategies now in place, we are confident that our strong and focused execution will translate into significant shareholder value in 2025 and beyond.

Management Comments

• Jeff Hackman, chief executive officer of Fennec Pharmaceuticals, stated that 2024 marked the beginning of a foundational transformation for Fennec, setting the stage for the PEDMARK strategy that we are utilizing throughout 2025 to realize our next phase of growth.
• Jeff Hackman also noted encouraging momentum in early 2025, particularly with adoption by academic institutions and new patient segments, reinforcing the value and need for PEDMARK.

Industry Context

Fennec's focus on reducing cisplatin-induced ototoxicity addresses a significant unmet need in pediatric oncology, as platinum-based therapies can cause permanent hearing loss in children. The commercial launch of PEDMARQSI in Europe and the ongoing clinical trial in Japan reflect the company's efforts to expand global access to its product.

Comparison to Industry Standards

• It is difficult to compare Fennec directly to other companies due to the unique nature of PEDMARK and its specific indication.
• However, the company's revenue growth and expansion into new markets can be compared to other specialty pharmaceutical companies focused on niche therapeutic areas.
• For example, companies like BioCryst Pharmaceuticals, which focuses on rare diseases, have demonstrated similar growth trajectories following successful product launches.
• The 40% year-over-year revenue growth is a strong indicator of market adoption and commercial success, which is a key metric for investors in the pharmaceutical industry.

Stakeholder Impact

• Shareholders: The financial results and business update provide information relevant to investment decisions.
• Patients: The continued commercialization of PEDMARK/PEDMARQSI offers a potential benefit to pediatric patients at risk of cisplatin-induced ototoxicity.
• Employees: The company's growth and expansion may create new opportunities for employees.
• Partners: The company's partnerships with Norgine and Inpharmus are important for expanding global access to PEDMARK/PEDMARQSI.

Next Steps

• Continue commercialization efforts for PEDMARK/PEDMARQSI in the U.S., Europe, and other regions.
• Await results from the Japan clinical trial (STS-J01) in the second half of 2025.
• Pursue addition of PEDMARK to the NCCN Drug and Biologics Compendium.
• Expand access to PEDMARQSI to cancer patients across the globe at risk of hearing loss.

Key Dates